Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis
This longitudinal observational study aimed to investigate environmental, familial, and individual factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP). Participants diagnosed according to Diagnostic and Statistical Manual of Mental Disorder
| Condition(s) | Methamphetamine Induced Psychosis |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This longitudinal observational study aimed to investigate environmental, familial, and individual factors associated with psychiatric symptom severity in participants diagnosed with methamphetamine-induced psychotic disorder (MP). Participants diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5-TR) criteria was followed/will be followed prospectively for one year. Sociodemographic characteristics, treatment adherence, perceived social support, addiction-related clinical variables, insight levels, and psychotic symptoms was assessed/will be assessed monthly using standardized psychometric instruments. The study aimed to identify predictors associated with relapse-remission patterns and changes in psychiatric symptoms over a one-year follow-up |
| Who can participate | * Methamphetamine-Induced Psychotic Disorder (MP) Group: \*Inclusion Criteria: * Diagnosis of MP according to DSM-5-TR * Medication-free for at least one month prior to admission * Age ≥ 18 years and \<65 years * Provided informed consent * Methamphetamine-Induced Psychotic Disorder (MP) Group: * Exclusion Criteria: * Hypertension * Diabetes mellitus * Chronic kidney disease * Rheumatoid arthritis * Systemic lupus erythematosus * Cardiac illness * Severe neurological disorders * Immunological or systemic illness * Primary psychiatric disorders other than MP * Alcohol use disorder |
| Ages | 18 Years to 65 Years |
| Sex | Male |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Elazığ Mental Health and Diseases Hospital |
| Locations | Elâzığ, Elâzığ, Turkey (Türkiye) |
| Start date | 2025-02-03 |
| NCT ID | NCT07459257 |
| Official listing | https://clinicaltrials.gov/study/NCT07459257 |